Literature DB >> 21081801

The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis.

H Cichoz-Lach1, K Celinski, P C Konturek, S J Konturek, M Slomka.   

Abstract

Nonalcoholic fatty liver disease is the most common chronic liver disease and nonalcocholic steatohepatitis (NASH) is its advanced form. Oxidative stress and hepatocyte apoptosis may be involved in pathogenesis of NASH and particularly in progress of NASH to liver fibrosis and cirrhosis, which are initiated by the inflammation and which promote the progress of the disease. The aim of this study was to evaluate the effects of melatonin and L-tryptophan on selected biochemical parameters of blood in patients with NASH. Forty five patients with NASH, confirmed by histopathological examination of liver biopsy samples, were admitted to the study. They were divided into three groups (I, II and III). The first group (group I, n=15) received preparation Essentiale forte 3 times a day and tryptophan 500 mg twice daily for 4 weeks. In the second group (group II, n=15), Essentiale forte three times a day was administered with melatonin 5 mg applied twice a day for 4 weeks. The third group (group III, n=15) received only Essentiale forte with placebo three times a day for 4 weeks. After four-week treatment we found statistically significant reduction in GGTP, triglycerides and proinflammatory cytokine levels in the melatonin-treated (group I) and the L-tryptophan-treated patients (group II). Plasma level of melatonin was significantly elevated in groups treated with tryptophan (group I) and melatonin (group II), but remained unchanged in placebo-treated group (group III). Among patients from the third group (treated with placebo) no statistically significant differences in the measured biochemical parameters were observed. The present study suggests that melatonin and tryptophan have the significant impact on the reduction in plasma levels of proinflammatory cytokines and may be useful in the treatment of patients with NASH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21081801

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  18 in total

1.  Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation.

Authors:  Ryan D Castle; Michelle A Williams; William C Bushell; J Adam Rindfleisch; Christine Tara Peterson; James Marzolf; Kimberly Brouwer; Paul J Mills
Journal:  J Inflamm Res       Date:  2021-09-22

Review 2.  The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Maryam Akbari; Vahidreza Ostadmohammadi; Reza Tabrizi; Kamran B Lankarani; Seyed Taghi Heydari; Elaheh Amirani; Russel J Reiter; Zatollah Asemi
Journal:  Inflammopharmacology       Date:  2018-06-15       Impact factor: 4.473

3.  Melatonin attenuates high fat diet-induced fatty liver disease in rats.

Authors:  Gregorios Hatzis; Panayiotis Ziakas; Nikolaos Kavantzas; Aggeliki Triantafyllou; Panagiotis Sigalas; Ioanna Andreadou; Konstantinos Ioannidis; Stamatios Chatzis; Konstantinos Filis; Alexandros Papalampros; Fragiska Sigala
Journal:  World J Hepatol       Date:  2013-04-27

Review 4.  Melatonin role preventing steatohepatitis and improving liver transplantation results.

Authors:  Eduardo Esteban-Zubero; Francisco Agustín García-Gil; Laura López-Pingarrón; Moisés Alejandro Alatorre-Jiménez; José Manuel Ramírez; Dun-Xian Tan; José Joaquín García; Russel J Reiter
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261

5.  Therapeutic strategies in inflammasome mediated diseases of the liver.

Authors:  Rafaz Hoque; Yoram Vodovotz; Wajahat Mehal
Journal:  J Hepatol       Date:  2012-12-21       Impact factor: 25.083

Review 6.  Melatonin supplementation and pro-inflammatory mediators: a systematic review and meta-analysis of clinical trials.

Authors:  Meysam Zarezadeh; Masoud Khorshidi; Mohammadreza Emami; Parisa Janmohammadi; Hamed Kord-Varkaneh; Seyed Mohammad Mousavi; Shimels Hussien Mohammed; Ahmad Saedisomeolia; Shahab Alizadeh
Journal:  Eur J Nutr       Date:  2019-11-02       Impact factor: 5.614

Review 7.  Melatonin in type 2 diabetes mellitus and obesity.

Authors:  Angeliki Karamitri; Ralf Jockers
Journal:  Nat Rev Endocrinol       Date:  2019-02       Impact factor: 43.330

8.  Anti-inflammatory effects of melatonin: A systematic review and meta-analysis of clinical trials.

Authors:  Joshua H Cho; Saumya Bhutani; Carole H Kim; Michael R Irwin
Journal:  Brain Behav Immun       Date:  2021-02-10       Impact factor: 7.217

9.  Melatonin levels in serum and ascitic fluid of patients with hepatic encephalopathy.

Authors:  Cezary Chojnacki; Marek Romanowski; Katarzyna Winczyk; Janusz Błasiak; Jan Chojnacki
Journal:  Gastroenterol Res Pract       Date:  2012-12-30       Impact factor: 2.260

10.  Role of serotonin in fatty acid-induced non-alcoholic fatty liver disease in mice.

Authors:  Yvonne Ritze; Maureen Böhle; Synia Haub; Astrid Hubert; Paul Enck; Stephan Zipfel; Stephan C Bischoff
Journal:  BMC Gastroenterol       Date:  2013-12-09       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.